Molecular profile of head and neck rhabdomyosarcomas: A systematic review and meta-analysis

• Published in: Oral surgery, oral medicine, oral pathology and oral radiology Vol. 134; no. 3; pp. 354 - 366
• Main Authors: Gallagher, Karen Patricia Domínguez, van Heerden, Willie, Said-Al-Naief, Nasser, Carlos, Roman, Arboleda, Lady Paola Aristizabal, Rodrigues-Fernandes, Carla Isabelly, Araújo, Anna Luíza Damaceno, Fonseca, Felipe Paiva, Pontes, Hélder Antônio Rebelo, Innocentini, Lara Maria Alencar Ramos, Romañach, Mário José, Vargas, Pablo Agustin, Lopes, Márcio Ajudarte, Santos-Silva, Alan Roger, Khurram, Syed Ali
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-09-2022
• ISSN: 2212-4403; 2212-4411
• DOI: 10.1016/j.oooo.2021.12.128

This systematic review aimed to identify the molecular alterations of head and neck rhabdomyosarcomas (HNRMS) and their prognostic values.
An electronic search was performed using PubMed, Embase, Scopus, and Web of Science with a designed search strategy. Inclusion criteria comprised cases of primary HNRMS with an established histopathological diagnosis and molecular analysis. Forty-nine studies were included and were appraised for methodological quality using the Joanna Briggs Institute Critical Appraisal tools. Five studies were selected for meta-analysis.
HNRMS predominantly affects pediatric patients (44.4%), and the parameningeal region (57.7%) is the most common location. The alveolar variant (43.2%) predominates over the embryonal and spindle cell/sclerosing types, followed by the epithelioid and pleomorphic variants. PAX-FOXO1 fusion was observed in 103 cases of alveolar RMS (79.8%). MYOD1 mutation was found in 39 cases of sclerosing/spindle cell RMS (53.4%). FUS/EWSR1-TFCP2 gene fusions were identified in 21 cases of RMS with epithelioid and spindle cell morphologies (95.5%). The 5-year overall survival rate of patients was 61.3%, and MYOD1 mutation correlated with significantly higher mortality.
The genotypic profile of histologic variants of HNRMS is widely variable, and MYOD1 mutation could be a potential prognostic factor, but more studies are required to establish this.